Heat shock protein 90 inhibition: rationale and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2012, v. 4, n. 4, p. 211, doi. 10.1177/1758834012445574
- By:
- Publication type:
- Article
Works matching IS 17588340 AND DT 2012 AND VI 4 AND IP 4
Results: 6
1
2
Pathways and biomarkers in breast cancer: latest evidence.
- Published in:
- Therapeutic Advances in Medical Oncology, 2012, v. 4, n. 4, p. 157, doi. 10.1177/1758834012450600
- By:
- Publication type:
- Article
3
Triple-negative breast cancer: are we making headway at least?
- Published in:
- Therapeutic Advances in Medical Oncology, 2012, v. 4, n. 4, p. 195, doi. 10.1177/1758834012444711
- By:
- Publication type:
- Article
4
Novel agents in renal carcinoma: a reality check.
- Published in:
- Therapeutic Advances in Medical Oncology, 2012, v. 4, n. 4, p. 183, doi. 10.1177/1758834012443725
- By:
- Publication type:
- Article
5
Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
- Published in:
- Therapeutic Advances in Medical Oncology, 2012, v. 4, n. 4, p. 167, doi. 10.1177/1758834012441049
- By:
- Publication type:
- Article
6
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2012, v. 4, n. 4, p. 173, doi. 10.1177/1758834012440015
- By:
- Publication type:
- Article